drugset / Trial / NCT06398925
Single Ascending Oral Dose Study to Investigate the Effects of OCT461201 in Healthy Volunteers
Phase 1
Completed
32 enrolled
Oxford Cannabinoid Technologies Holdings PLC
Simbec-Orion Group · collab
RandomizedSequentialQuadruple-blindTreatment
Summary
A study in healthy volunteers to evaluate the safety, tolerability and pharmacokinetics of OCT461201. The study included a screening period, a single dose of study treatment or placebo and a follow up period.
Timeline
- Start
- 2023-07-26
- Primary completion
- 2023-09-25
- Completion
- 2023-09-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | OCT461201 | Unknown | 50 mg | Oral |
| Subject | OCT461201 | Unknown | 100 mg | Oral |
| Subject | OCT461201 | Unknown | 150 mg | Oral |
| Subject | OCT461201 | Unknown | 450 mg | Oral |
Indications
No indication recorded.